GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AEON Biopharma Inc (AMEX:AEON) » Definitions » Accounts Receivable

AEON Biopharma (AEON Biopharma) Accounts Receivable : $0.00 Mil (As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is AEON Biopharma Accounts Receivable?

Accounts Receivable are created when a customer has received a product but has not yet paid for that product. AEON Biopharma's accounts receivables for the quarter that ended in Mar. 2024 was $0.00 Mil.

Accounts receivable can be measured by Days Sales Outstanding.

In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. AEON Biopharma's Net-Net Working Capital per share for the quarter that ended in Mar. 2024 was $-5.24.


AEON Biopharma Accounts Receivable Historical Data

The historical data trend for AEON Biopharma's Accounts Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AEON Biopharma Accounts Receivable Chart

AEON Biopharma Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Accounts Receivable
0.27 - - - -

AEON Biopharma Quarterly Data
Dec19 Jun20 Dec20 Jun21 Dec21 Sep22 Dec22 Mar23 Sep23 Dec23 Mar24
Accounts Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only - - - - -

AEON Biopharma Accounts Receivable Calculation

Accounts Receivable is money owed to a business by customers and shown on its Balance Sheet as an asset.


AEON Biopharma Accounts Receivable Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.

AEON Biopharma's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:

2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), AEON Biopharma's accounts receivable are only considered to be worth 75% of book value:

AEON Biopharma's Net-Net Working Capital Per Share for the quarter that ended in Mar. 2024 is calculated as:

Net-Net Working Capital Per Share
=(Cash And Cash Equivalents+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(1.558+0.75 * 0+0.5 * 0-201.413
-0-0)/38.1203
=-5.24

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.

If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.

Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.


AEON Biopharma Accounts Receivable Related Terms

Thank you for viewing the detailed overview of AEON Biopharma's Accounts Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


AEON Biopharma (AEON Biopharma) Business Description

Traded in Other Exchanges
N/A
Address
4040 MacArthur Boulevard, Suite 260, Newport Beach, CA, USA, 92660
AEON Biopharma Inc is a clinical stage biopharmaceutical company focused on developing of its proprietary botulinum toxin complex ABP-450 (prabotulinumtoxinA) injection for therapeutic indications.
Executives
Strathspey Crown Holdings Group, Llc 10 percent owner 4040 MACARTHUR BLVD., SUITE 210, NEWPORT BEACH CA 92660
Priveterra Sponsor, Llc 10 percent owner 300 SE 2ND STREET, SUITE 600, FORT LAUDERDALE FL 33301
Daewoong Co., Ltd 10 percent owner 244, GALMACHI-RO, JUNGWON-GU, SEONGNAM-SI, GYEONGGI-DO M5 13211
Alexander Blair Wilson officer: Exec VP, CLO & Corp Secretary 5 PARK PLAZA, SUITE 1750, IRVINE CA 92614
Chad Oh officer: Chief Medical Officer C/O AEON BIOPHARMA, INC., 4040 MACARTHUR BOULEVARD, SUITE 250, NEWPORT BEACH CA 92660
Marc Forth director, officer: Chief Executive Officer C/O AEON BIOPHARMA, INC., 4040 MACARTHUR BLVD., SUITE 260, NEWPOER BEACH CA 92660
Jost Fischer director C/O AEON BIOPHARMA, INC., 4040 MACARTHUR BOULEVARD, SUITE 250, NEWPORT BEACH CA 92660
Oleg Grodnensky 10 percent owner 300 SE 2ND STREET, SUITE 600, FORT LAUDERDALE FL 33301
Vikram Malik 10 percent owner 17901 VON KARMAN AVENUE, SUITE 150, IRVINE CA 92614
Peter A Reynolds officer: Chief Financial Officer 27442 PORTOLA PARKWAY, SUITE 200, FOOTHILL RANCH CA 92610
Robert J Palmisano director, 10 percent owner 110 HARTWELL AVENUE, LEXINGTON MA 02173
Shelley B Thunen director C/O RXSIGHT, INC., 100 COLUMBIA, ALISO VIEJO CA 92656
Eric G Carter director C/O KING PHARMACEUTICALS, INC., 501 FIFTH STREET, BRISTOL TN 37620
Plc Barclays 10 percent owner 1 CHURCHILL PLACE, CANARY WHARF, LONDON X0 E14 5HP
David Meredith officer: Chief Legal Officer&Secretary 300 SE 2ND STREET, SUITE 600, FORT LAUDERDALE FL 33301